GlassScriptPhysician profile
Brian Michael Mcdermott
NPI 1710454111
$3,335.15
in general payments reported to CMS, 2019-2025
22 companies · $835 in 2025
The $835 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.29 · 2022: $489 · 2023: $1,313 · 2024: $631 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $441.25 | 2023-2025 | Repatha, Tepezza, Otezla |
| Alexion Pharmaceuticals, INC. | $332.79 | 2023-2025 | Ultomiris |
| Collegium Pharmaceutical, INC. | $327.12 | 2022-2025 | Belbuca |
| Abbvie INC. | $241.78 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $228.49 | 2021-2024 | Airsupra |
| Boston Scientific Corporation | $176.88 | 2022-2025 | Watchman Flx |
| Cordis US Corp. | $164.84 | 2023 | S.M.A.R.T. |
| Genzyme Corporation | $149.61 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $145.61 | 2025 | |
| Neurocrine Biosciences, INC. | $139.29 | 2022-2025 | |
| Medtronic, INC. | $135.21 | 2023 | Interstim |
| Novo Nordisk INC | $123.03 | 2022 | |
| Sage Therapeutics, LLC | $120.00 | 2023 | |
| Madrigal Pharmaceuticals | $107.19 | 2025 | Rezdiffra |
| Abiomed | $105.26 | 2024 | Impella |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $99.84 | 2024 | Epclusa |
| Kyowa Kirin, INC. | $73.16 | 2025 | |
| Sumitomo Pharma America, INC. | $72.26 | 2023 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $69.30 | 2025 | Rexulti |
| Veryan Medical Incorporated | $48.69 | 2023 | Biomimics 3d Vascular Stent System |
| Averitas Pharma INC. | $17.58 | 2023 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $15.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mcdermott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.